NEW YORK (360Dx) – Arquer Diagnostics announced today that it has been awarded a  £70,000 ($86,038) grant from Innovate UK to prepare for a clinical study of its ELISA-based noninvasive prostate cancer test.

The test — called MCM5-ELISA — detects minichromosome maintenance, a protein biomarker of dividing cancer cells. The planned study will evaluate the test using urine and semen samples from up to 100 patients and help the company design a larger clinical trial that is expected to start later this year.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Mar
08
Sponsored by
Swift Biosciences

This webinar will discuss an optimized protocol for methyl-CpG binding domain sequencing (MBD-seq), which enables comprehensive, adequately powered, and cost-effective large-scale methylome-wide association studies (MWAS) of almost all 28 million CpG sites in the genome.

Mar
13

This webinar will share how clinical genetics labs can integrate cytogenetics and molecular data to assess abnormalities using a single sample on a single workflow platform.

Apr
03

Proximity ligation technology generates multi-dimensional next-generation sequencing data that is proving to solve unmet needs in genomic research.